Pancreatic Cancer
1,890
292
393
795
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
285 trials with published results (15%)
Research Maturity
795 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.2%
231 terminated out of 1890 trials
77.5%
-9.0% vs benchmark
6%
122 trials in Phase 3/4
36%
285 of 795 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 795 completed trials
Clinical Trials (1890)
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Pancreatic Cancer Genetics
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Integrated Cancer Repository for Cancer Research
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
A 2-part Phase 1/2 Open-label Trial on ODM-212
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
ZN-c3 + Gemcitabine in Pancreatic Cancer